Navigation Links
Study: FOLFIRINOX Followed by Chemoradiation Shows Substantial Activity in Locally Advanced Pancreatic Cancer
Date:5/8/2013

Durham, NC (PRWEB) May 08, 2013

Treatment with neoadjuvant 5-FU, oxaliplatin, irinotecan, and leucovorin (FOLFIRINOX) followed by chemoradiation shows substantial activity in patients with locally advanced pancreatic cancer, with conversion to surgical resectability with curative intent in more than 20% of patients. In a retrospective study published in The Oncologist, Jason Faris, M.D., Medical Oncologist at the Massachusetts General Hospital Cancer Center in Boston, and colleagues described their institutional experience with the FOLFIRINOX treatment protocol in patients with locally advanced pancreatic cancer.

Nearly one-third of patients with newly diagnosed pancreatic cancer present with locally advanced disease, which is associated with a median overall survival of approximately one year. Effective treatment of locally advanced pancreatic cancer may permit resection for patients with initially unresectable disease, but to date no standard of care has been defined for this patient population. Although treatment with FOLFIRINOX is associated with improved response rate, progression-free survival, and overall survival in the metastatic setting, this regimen has not been studied extensively in patents with locally advanced pancreatic cancer.

The current study included all patients (n = 22) with locally advanced prostate cancer who began treatment with FOLFIRINOX between July 2010 and February 2012 at the Massachusetts General Hospital Cancer Center. The neoadjuvant FOLFIRINOX regimen consisted of 5-FU administered as a bolus of 400mg/m2, bolus leucovorin 400mg/m2 followed by continuous infusion at 1200mg/m2/day for 46 hours, oxaliplatin 85mg/m2, and irinotecan 180mg/m2. For 20 patients, FOLFIRINOX was followed by chemoradiation with continuous infusion 5-FU or capecitabine and intensity-modulated radiation therapy (50.4 Gy).

Patients received a median of 8 cycles of neoadjuvant FOLFIRINOX, including a
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. New Study: Valtrex (Valacyclovir) Side Effects Target the Brain; polyDNA Suggests a Natural Herpes Remedy
2. Study: Brain Imaging After Mild Head Injury/Concussion Can Show Lesions
3. RPCI-Led Study: FAK Inhibitor Proves Effective Against Brain Tumors in Preclinical Studies
4. Nature Materials study: Boosting heat transfer with nanoglue
5. New Study: Health Professionals Support Biotechnologys Use In Food Products And Sustainable Farming
6. Nature Materials study: Graphene invisible to water
7. Breaking Study: ICU Medicals Tego® Needlefree Connector Proves More Cost Effective Than Traditional Central Venous Catheter Locks
8. Preclinical study shows heroin vaccine blocks relapse
9. New Study on Cordyceps Sinensis (Hirsutella Sinensis) Shows Anti-Inflammatory Properties
10. Patheon to Showcase High Potency Capabilities at Upcoming Tradeshows
11. Analysis of 2012 New Drug Application Approvals (NDAs) Shows Bio/Pharma Contract Manufacturers Treading Water
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... , March 30, 2015  NuGene International, ... subsidiary corporation, NuGene BioPharma, Inc. has added another ... Dr. Guan is an internationally recognized researcher ... his college education at Peking University, ... degree from the University of North Carolina, Chapel ...
(Date:3/30/2015)... ROCKVILLE, Md. , March 30, 2015 ... company dedicated to the acquisition, development and commercialization of ... for the global market with a commercial focus on ... China Food and Drug Administration (CFDA) has approved the ... trial in ovarian clear cell carcinoma (OCCC) patients for ...
(Date:3/30/2015)... , March 30, 2015  Spherix Incorporated (Nasdaq: ... to the fostering and monetization of intellectual property, ...  Case No. 3:13-cv-03494-M and  Spherix v. Uniden , ... District Court for the Northern District of ... Spherix v. Verizon, Case No. 1:14-cv-00721-GBL-TCB, ...
(Date:3/30/2015)... N.J. , March 30, 2015  Naldemedine, ... under development by Shionogi & Co., Ltd., met ... III study (COMPOSE I) for the treatment of ... non-cancer pain receiving opioid therapy. Study results showed ... statistically significantly improved the frequency of spontaneous bowel ...
Breaking Biology Technology:UCI Professor Zhibin Guan Joins NuGene Advisory Board 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 2Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 3Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3
... , CINCINNATI, Sept. 16 Kendle (Nasdaq: ... the Company will participate in the upcoming UBS Global Life Sciences ... Hotel in New York City. , , (Logo: ... Kendle,s formal presentation will be given by Chairman and Chief ...
... ... other technologies for professional purposes and treatment decisions , ... New York, NY (PRWEB) September 16, 2009 -- ... biotech, and device corporate and product websites on a regular basis, according to pharmaceutical ...
... SOUTH SAN FRANCISCO, Calif., Sept. 16 Poniard ... focused on innovative oncology therapies, today announced that Jerry McMahon, ... overview at the 2009 UBS Global Life Sciences Conference on ... the Grand Hyatt Hotel in New York City. , ...
Cached Biology Technology:Kendle to Present at UBS Global Life Sciences Conference 2Oncologists Visit Pharma Sites and Post Professional Content Online More Frequently than the Average Physician 2Oncologists Visit Pharma Sites and Post Professional Content Online More Frequently than the Average Physician 3Oncologists Visit Pharma Sites and Post Professional Content Online More Frequently than the Average Physician 4Poniard Pharmaceuticals to Present at the 2009 UBS Global Life Sciences Conference 2
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and ... addition of the "Global Iris Recognition Market 2015-2019" ... forecast the Global Iris Recognition market to grow at ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
(Date:3/23/2015)... NEW YORK , March 23, 2015   ... digital property management company, today announced that the Company ... platform for both enterprise and consumers at Connect:ID on ... D.C. HOYOS Labs will highlight the IEEE ... 1U TM ; and enterprise access control system. ...
(Date:3/20/2015)... Conn. , March 20, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... smart wallet is one of the products featured in ... March 20th at 11:00 PM EST on the DIY ... to Las Vegas , site of ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
... When prehistoric fish made their first forays onto land, ... in the online open access journal, BMC Evolutionary Biology, ... viewed their new environment in full colour. A ... Biomedical Sciences, University of Queensland, Brisbane, Australia, analysed retinas ...
... been uncovered from old experiments by researchers at the ... Hospital. The finding suggests that useful information about many ... data. "We,ve devised a fairly simple way to ... disease genes for further genetic study," said Atul Butte, ...
... Severely restricting calories leads to a longer life, scientists ... the first time that such a diet also can ... inevitable progression to physical disability and loss of independence. ... restriction, showed that the diet reduces the amount of ...
Cached Biology News:Stanford/Packard researchers find disease genes hidden in discarded data 2Stanford/Packard researchers find disease genes hidden in discarded data 3Severely restricted diet linked to physical fitness into old age 2
Artisan™ Wash Solution (x 50) Additional Information: EU regulatory status: CE US regulatory status: IVD ...
... Gene Cycler unit is an inexpensive personal or ... the PCR process. Lightweight, with a small footprint, ... anywhere, including the researcher's desk. , The Gene ... who do not have access to a large ...
... The IHC Select Immunophosphatase Secondary Detection System ... IHC Select Prediluted Primary Antibody reagents, which ... qualitative identification of antigens by light microscopy ... Secondary Detection System may also be used ...
... RNA stain is used to stain and ... agarose gels and does not interfere with ... nm transilluminator, the stain emits a red-orange ... film or with a CCD camera-based gel ...
Biology Products: